Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. MindMaze Therapeutics Holding's accounts receivables for the quarter that ended in Dec. 2025 was CHF1.02 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
MindMaze Therapeutics Holding's Days Sales Outstanding for the quarter that ended in Dec. 2025 was 290.81.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. MindMaze Therapeutics Holding's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was CHF-0.02.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
MindMaze Therapeutics Holding's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), MindMaze Therapeutics Holding's accounts receivable are only considered to be worth 75% of book value:
MindMaze Therapeutics Holding's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
MindMaze Therapeutics Holding Accounts Receivable Related Terms
MindMaze Therapeutics Holding Accounts Receivable Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Accounts Receivable of CHF1.02 Mil mean?
MindMaze Therapeutics Holding (XSWX:MMTX) has a Accounts Receivable of CHF1.02 Mil as of Dec. 2025. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on MindMaze Therapeutics Holding and its competitors.
Is MindMaze Therapeutics Holding's Accounts Receivable too high?
MindMaze Therapeutics Holding's current Accounts Receivable is CHF1.02 Mil. Overall, MindMaze Therapeutics Holding has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Accounts Receivable compare to VRTX and REGN?
MindMaze Therapeutics Holding's Accounts Receivable of CHF1.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Biotechnology company?
A good Accounts Receivable depends on the Biotechnology industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current Accounts Receivable is CHF1.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (XSWX:MMTX) has a current Accounts Receivable of CHF1.02 Mil. The current Accounts Receivable is CHF1.02 Mil. MindMaze Therapeutics Holding's overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For MindMaze Therapeutics Holding (XSWX:MMTX), the current Accounts Receivable is CHF1.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MindMaze Therapeutics Holding Business Description
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
4GF Score
Get the complete analysis for XSWX:MMTX
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MMTX has been successfully added to your 
